

March 17, 2022

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir / Madam,

Sub: Press Release – signing of voluntary license for Pfizer Covid19 oral treatment– nirmatrelvir

We enclose a copy of the Press Release that is being issued by the Company, announcing that the Company along with its subsidiaries is signing of sub-license agreement for a generic version of Pfizer's Covid19 oral treatment nirmatrelvir with the UN backed Medicines Patent Pool (MPP), headquartered in Geneva, for manufacturing and supplying the generic drug product to 95 countries including India.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary



Encl: As above

Hyderabad, India, March 17, 2022

Aurobindo announces signing of voluntary license for Pfizer Covid19 oral treatment– nirmatrelvir

Aurobindo Pharma Limited (along with its subsidiaries together referred to as “Aurobindo”) is pleased to announce the signing of sub-license agreement for a generic version of Pfizer’s Covid19 oral treatment nirmatrelvir with the UN backed Medicines Patent Pool (MPP), headquartered in Geneva, for manufacturing and supplying the generic drug product to 95 countries including India. Earlier MPP signed voluntary licensing agreement with Pfizer for sub-licensing this Covid-19 treatment product to qualified generic drugmakers.

Nirmatrelvir in combination with ritonavir co-pack has received emergency use/conditional authorization for Covid-19 treatment in certain populations by USFDA, the UK Medicines and Healthcare products Regulatory Agency (UKMHRA and nearly 50 other countries).

Mr.K. Nithyananda Reddy, Vice Chairman & Managing Director, Aurobindo said, “ We are extremely happy to partner with Medicines Patent Pool to bring this treatment option for Covid19 to low & middle income countries. Aurobindo has already developed and commercialized ritonavir which is used as a booster along with nirmatrelvir. We are excited to work on this molecule and will soon make it available commercially at an affordable price for these markets after due process of registration and approval in various countries including DCGI in India. This combination will be a very valuable addition to our portfolio along with Molnalu® (molnupiravir) for the treatment of Covid19.”

For nirmatrelvir and ritonavir molecules, like other antivirals, Aurobindo enjoys backward integration with in-house API manufacturing which equips it with stronger control on supply chain and cost efficiencies. The product will be manufactured at the Company’s state of the art manufacturing facilities in India that are approved by global regulatory agencies including USFDA and UKMHRA. The Company has adequate capacities to meet the global demand across the 95 Countries including India.

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 155 countries.

The company has 27 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company’s robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

To know more, please log on to www.aurobindo.com

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District, Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd. off.: Plot No.2, Maithrivihar, Ameerpet, Hyderabad-500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833

For further information or queries, please contact:

Shashank Parkhe | Deepti Thakur

Investor Relations | Corporate Communications

Phone: +91 40 66725401 / 66725000

Email: ir@aurobindo.com

Disclaimer:

This press release contain statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

www.aurobindo.com

PAN No. AABCA7366H

Corp. Off.: Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,
Hyderabad – 500 032, Telangana, India. Tel : +91 40 6672 5000 / 6672 1200 Fax: +91 40 6707 4044.

Regd.off.: Plot No. 2, Maithrivihar, Ameerpet, Hyderabad-500038 T.S., INDIA Tel: +91 40 2373 6370/2374 7340 Fax: +91 40 2374 1080/2374 6833